A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination With Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination With Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Isatuximab (Primary) ; Carfilzomib
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Initial results of safety and efficacy data (n=11) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 05 Dec 2016 According to Sanofi Genzyme media release, findings from this study were presented during a poster session at the American Society of Hematology meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top